Development of a novel combination immunotherapy with NKT cells and antibody therapy

2016 Fiscal Year Final Research Report

• Project/Area Number: 26861119
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory surgery
• Research Institution: Tokyo Women's Medical University (2015-2016); Chiba University (2014)
• Principal Investigator: Kamata Toshiko 東京女子医科大学, 医学部, 助教 (60586692)
• Research Collaborator: MOTOHASHI Shinichiro 千葉大学, 大学院医学研究院・免疫細胞医学, 教授 (60345022)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: NKT細胞治療 / 抗PDL1抗体 / 癌免疫治療

Outline of Final Research Achievements

There are few researches on the function of PD-1/PDL1 in human NKT cells. In our research, we found that PD-1 was upregulated in activated NKT cells and NKT cells derived from lung cancer patients.
Cytokine secretion and anti-tumor functions of NKT cells improved when the ligand for PD-1 (PDL1) was blocked on antigen presenting cells and tumor cells. We also found that these NKT cells improved anti-tumor immunity through interaction with other immune cells. Our results imply that the combination of anti-PD-1/PDL1 with NKT cell-mediated immunotherapy would improve the treatment outcomes in cancer patients. These data may become the basis for future clinical trials.

Free Research Field

肺癌免疫治療、外科治療